Literature DB >> 20842207

Immune globulin subcutaneous (human), 20% liquid.

.   

Abstract

Entities:  

Year:  2010        PMID： 20842207      PMCID： PMC2935641     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  24 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin.

Authors:  Stacey Radinsky; Vincent R Bonagura
Journal:  J Allergy Clin Immunol       Date:  2003-09       Impact factor: 10.793

Review 3.  Pharmacy considerations for the use of IGIV therapy.

Authors:  Sachin Shah
Journal:  Am J Health Syst Pharm       Date:  2005-08-15       Impact factor: 2.637

4.  Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Authors:  J M Boyle; R H Buckley
Journal:  J Clin Immunol       Date:  2007-06-19       Impact factor: 8.317

Review 5.  Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

Authors:  Ann Gardulf
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

6.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

7.  Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors:  John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal:  J Clin Immunol       Date:  2010-05-08       Impact factor: 8.317

8.  High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy.

Authors:  M Berger; T R Cupps; A S Fauci
Journal:  JAMA       Date:  1982-05-28       Impact factor: 56.272

Review 9.  Human primary immunodeficiency diseases: a perspective.

Authors:  Alain Fischer
Journal:  Nat Immunol       Date:  2004-01       Impact factor: 25.606

Review 10.  Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency.

Authors:  C Bacchelli; S Buckridge; A J Thrasher; H B Gaspar
Journal:  Clin Exp Immunol       Date:  2007-09       Impact factor: 4.330
View more
  1 in total

1.  Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration.

Authors:  Anas M Fathallah; Michael R Turner; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2014-12-20       Impact factor: 1.627
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.